Neurocrine Biosciences | Actif À Court Terme



Current Assets Changement Date
AbbVie USD 25.58B 2.2B 2024-12
Acadia Pharmaceuticals USD 870.94M 67.38M 2025-03
Agios Pharmaceuticals USD 968.62M 3.02M 2025-03
ALKERMES USD 1.48B 63.7M 2025-03
Alnylam Pharmaceuticals USD 3.27B 27.03M 2025-03
Amgen USD 26.93B 2.1B 2025-03
Biogen USD 7.63B 169.2M 2025-03
BioMarin Pharmaceutical USD 3.47B 235.48M 2025-03
Cytokinetics USD 956.05M 151.89M 2025-03
Dynavax Technologies USD 815.97M 32.97M 2025-03
Exelixis USD 1.4B 71.08M 2025-04
Gilead Sciences USD 19.17B 4.39B 2024-12
Halozyme Therapeutics USD 1.26B 176.69M 2025-03
Incyte USD 3.23B 7.24M 2025-03
Ionis Pharmaceuticals USD 2.42B 201.36M 2025-03
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Pfizer USD 45.86B 4.5B 2025-03
Prothena USD 485.41M 49.57M 2024-12
Regeneron Pharmaceuticals USD 17.57B 9.64B 2025-03
Repligen USD 1.03B 33.58M 2025-03
Sarepta Therapeutics USD 2.43B 640.93M 2025-03
Teva Pharmaceutical Industries USD 11.53B 1.02B 2025-03
Ultragenyx Pharmaceutical USD 817.12M 17.52M 2024-12
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



Neurocrine Biosciences Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.